Untransfected and TRPV2+ Ishikawa cells were treated with CIS and DOX (from 0.0064 μg/mL to 100 μg/mL), and PAC (from 0.00025 μg/mL to 4 μg/mL) for 72 h. Here, TRPV2 is linked to in situ carcinoma.